In Lancet Oncology:
A phase III trial comparing RT + capecitabine vs 5FU for rectal cancer - fortunately has confirmed what is already common practice in the US - capecitabine proved no worse (by their criteria). All trends as well favored capcitabine for disease control. Capcitabine proved more toxic however, in all but leukopenia.
[Articles] Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial: Capecitabine could replace fluorouracil in adjuvant or neoadjuvant chemoradiotherapy regimens for patients with locally advanced rectal cancer.